Analysis of Clinical Trial Logistic Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
According to the new study published by Fact.MR, the global clinical trial logistic market is evaluated to generate a turnover of US$ 4.1 billion in 2024. The market has been analyzed to register a CAGR of 9.3% to reach a valuation of US$ 9.98 billion by the end of 2034.
Clinical trials are increasing due to the growing need for innovative medications and medical technologies. This is driving up the requirement for effective logistics services that manage complicated trial supplies and guarantee regulatory compliance. As clinical trials are carried out in more locations across the globe, complex logistical solutions are needed to coordinate the movement of supplies through several regulatory frameworks.
Clinical trial logistics are becoming more transparent, more efficient, and more secure because of the incorporation of advanced technology, such as blockchain, real-time tracking, and GPS monitoring. It is now essential to ensure adherence to several international requirements, including Good Distribution Practices (GDP). Because of this, there is a need for specialized logistics companies with knowledge of navigating intricate regulatory environments.
The North American region is estimated to lead with 33.6% of the worldwide clinical trial logistic market share in 2024. The reasons behind this are a well-established healthcare system, a large number of ongoing clinical trials, and substantial investments in R&D activities. Effective clinical trial operations are supported by a strong logistical infrastructure, which includes advanced storage and transportation facilities.
Based on service, the manufacturing segment is analyzed to account for 31.1% portion of the revenue share in 2024 due to its crucial role in the production of investigational medicinal products (IMPs) and medical devices needed for clinical trials. The logistics of the supply chain for raw materials, active pharmaceutical ingredients (APIs), and completed goods are covered in this segment. These logistics are essential to the effective execution of trials.
| Report Attributes | Details |
|---|---|
| Clinical Trial Logistic Market Size (2024E) | US$ 4.1 Billion |
| Forecasted Market Value (2034F) | US$ 9.98 Billion |
| Global Market Growth Rate (2024 to 2034) | 9.3% CAGR |
| North America Market Share (2024E) | 33.6% |
| Western Europe Market Value (2024E) | US$ 929.27 Million |
| South Asia & Pacific Market Growth Rate (2024 to 2034) | 11.9% CAGR |
| Manufacturing Segment Value (2034F) | US$ 3.32 Billion |
| Phase I Segment Value (2034F) | US$ 4.34 Billion |
| Key Companies Profiled | Alamc Group; Catalent Inc.; PCI Services; Parexel International Corporation; Sharp Packaging Services; Biocair; O&M Movianto; KLIFO A/S; Thermo Fisher Scientific Inc.; Capsugel; UDG Healthcare Plc.; DHL International GmbH; Bilcare Limited; PRA Health Sciences Inc.; Eurofins Scientific; Marken; Seveillar Clinical Trial Supplies Pvt. Ltd.; N-SIDE; Crown Couriers; AIT Worldwide Logistics, Inc.; FedEx; Movianto; Patheon; Fisher Clinical Services; Royal Cargo; Fet Logistics; Avantor Clinical Services |
Clinical trial logistics is an administration that is in charge of giving clinical logistics required to perform clinical studies of medical devices or drugs as per convention and applicable regulatory requirements. This procedure includes oversight of the planning, packaging, labeling, forecasting, sourcing, distribution, and clinical logistics for government and business supports whose studies are in stage 1-4 clinical trials.
Clinical trial logistics coordinate with numerous third-party technicians and vendors to confirm whether study drugs accessible are in adequate amount and quality at different phases of clinical distribution. Clinical trials are supported and subsidized by government offices, establishments, hospitals, doctors, drug or biotechnology organizations, advocacy groups, or other organizations.
Extensive developments happening in the field of healthcare and medication, particularly in terms of testing and improvement of new operations, medications, and investigations, are principally liable for driving the worldwide clinical trial logistic market. This is mostly because of the way that quality management is required particularly regarding providing important apparatus and other equipment required for carrying out clinical trial-based activities.
The rising number of clinical trial procedures by drug companies will be liable to emphatically affect the clinical trial logistic market. As indicated by ClinicalTrials.Gov, the U.S. carries out the largest number of clinical trial procedures each year. In addition, an expanding number of contract research organizations (CRO), and medical care suppliers, are a portion of the components driving the development of the market.
Besides, the development of the market is additionally ascribed to the expanding interest in Over-the-counter (OTC) prescriptions, such as Vitamins, Minerals, and Supplements (VMS), basic common cough and cold medications, gastrointestinal medications, and dermatology products. The rising significance of quick-track help in the medical care area is likewise driving the market for clinical trial logistics.
Also, diminishing the distribution cost by making a single source distribution channel is further driving the interest in clinical trial logistics. In addition, mechanical advances happening in drug and biologics, particularly in testing and development of new operations, products, drugs, and experiments, are vigorously liable for driving the worldwide clinical trial logistic market.
There has been an expanding frequency of chronic and infectious diseases is expected to increase at a rapid rate during the estimated period. Chronic diseases, including cardiovascular infections, obesity, malignant growth, and diabetes are influencing several people around the world.
The ascent in these non-communicable chronic diseases is because of urbanization and the selection of undesirable ways of life. As per the Centers for Disease Control and Prevention (CDC) over 60% of preventable deaths occur are caused because of non-communicable diseases. In potentially high-growth countries, 48% of such deaths happen in people over 70 years old.
The rate of chronic diseases is likewise expanding quickly in Africa. The rate of infectious diseases, such as HIV, hepatitis, and other viral infections has additionally been ascending worldwide. As indicated by the World Health Organization (WHO) estimate that 13 million deaths would happen because of infectious diseases by 2050.
These elements have prompted increasing demand for clinical trial logistics as an increase in chronic diseases means a rise in the need for drugs, which in turn increases the need for clinical trials for drug development, and are relied upon to drive the clinical trial logistic market.
High costs in managing patients, equipment expected to carry on ethical clinical trials, and the absence of fundamental proficiency to execute such exercises just as time utilization are the main considerations hampering the clinical trial logistic market. In addition, the development of the worldwide clinical trial logistic market for the pharmaceutical industry is hampered by longer clinical trial investigation time and complex clinical trial regulations.
Likewise, delays in site identifications, budget negotiations, delays in contracts, and the inability to recruit volunteers eventually decelerate the clinical trial investigation process. In addition, the absence of proficiency to proliferate such exercises in emerging areas where critical clinical needs exist likewise goes about as a central obstacle to the market's extension.
The major players operating in the Clinical Trial Logistic market include
The global clinical trial logistic market is segmented based on region into North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East, and Africa. North America represented the biggest portion of the clinical trial logistic market because of a high number of research and development exercises in the area of advanced healthcare infrastructure, drug discovery, and the presence of worldwide drug and biotechnology organizations that do clinical trials. Europe represented the second biggest share in terms of income inferable from high medical care ventures and rising government subsidizing.
Asia Pacific (East and South Asia) is additionally seeing huge development because of rising unmet medical care needs and expanded government subsidizing research activities. Appeal for medicines because of the developing geriatric populace will likewise increase the market for clinical trial logistics in Asia Pacific. Additionally, significant drug organizations are outsourcing their drug development services to several countries, such as India, Malaysia, China, and Singapore, which is driving the development of the clinical trial logistic market in the area.
The Middle East and Latin America are relied upon to be the imminent business sectors due to developing access to information, high malignant growth trouble, improving patient training, and access to new drugs for research centers. Nonetheless, long courses for regulatory approval, absence of training, absence of economic investment, and absence of workforce taking part in clinical trials in Latin America and the Middle East are estimated to hamper the clinical trial logistic market growth.
With the point of expanding net revenues and extending the item portfolio to new business sectors, Logistics companies are entering into strategic agreements with healthcare companies for better distribution channels and better reach to the clients and outsourcing clinical trial logistics exercises to CROs.
Numerous organizations attempting to grow in creating geologies are additionally moving to supply and logistics services providers for better market reach. For instance, the expense of clinical trials in China is generally 20% not as much as what it is in the US.
It has brought about decreased expenditures and expanded interest in R&D to direct clinical trials. The interest in efficient supply and logistics of trial samples amongst pharma organizations, CROs, and the food and drug organization, will keep on driving the market in the years to come. Accordingly, the clinical trial logistic market is relied upon to make critical increases.
Interest in orphan and biological drugs will be a major component that boosts the clinical trial logistic market. There is an ascending development of new medications, treatments, and clinical devices, which will enhance the development of the market. Innovative advances happening in drug and biologics, particularly in zones of testing and improvement of new operations, products, medications, and analyses, are vigorously liable for driving the worldwide clinical trial logistic market.
Several organizations are hugely contributing to acquiring technologies and logistics in clinical trial exercises in the cycle, therefore spiking the supply of essential equipment. Along these lines, the worldwide clinical trial logistic market is relied upon to extend with colossal development over the forecast period. At the same time, the expanding concentration by the suppliers towards limiting overage rates avoiding shortages and minimizing overage incidences, advancing packaging and production, and adjusting shipment and supply costs are expanding the interest in the proficient clinical trial logistic market.
How much is the current worth of the clinical trial logistic market?
The clinical trial logistic market is of US$ 4.1 billion worth in 2024.
Why does the clinical trial logistic market have higher growth potential?
Extensive development in healthcare and medication is driving the clinical trial logistic market.
Where are most opportunities for clinical trial logistic industry players?
Third-party technicians and vendors are offering the most opportunities for the clinical trial logistic industry players.
Table 1: Global Market US$ Mn Forecast by Region
Table 2: Global Market US$ Mn Forecast by Service
Table 3: Global Market US$ Mn Forecast by Phase
Table 4: Global Market US$ Mn Forecast by Therapeutic Area
Table 5: Global Market US$ Mn Forecast by End User
Table 6: North America Market US$ Mn Forecast by Country
Table 7: North America Market US$ Mn Forecast by Service
Table 8: North America Market US$ Mn Forecast by Phase
Table 9: North America Market US$ Mn Forecast by Therapeutic Area
Table 10: North America Market US$ Mn Forecast by End User
Table 11: Latin America Market US$ Mn Forecast by Country
Table 12: Latin America Market US$ Mn Forecast by Service
Table 13: Latin America Market US$ Mn Forecast by Phase
Table 14: Latin America Market US$ Mn Forecast by Therapeutic Area
Table 15: Latin America Market US$ Mn Forecast by End User
Table 16: Western Europe Market US$ Mn Forecast by Country
Table 17: Western Europe Market US$ Mn Forecast by Service
Table 18: Western Europe Market US$ Mn Forecast by Phase
Table 19: Western Europe Market US$ Mn Forecast by Therapeutic Area
Table 20: Western Europe Market US$ Mn Forecast by End User
Table 21: Eastern Europe Market US$ Mn Forecast by Country
Table 22: Eastern Europe Market US$ Mn Forecast by Service
Table 23: Eastern Europe Market US$ Mn Forecast by Phase
Table 24: Eastern Europe Market US$ Mn Forecast by Therapeutic Area
Table 25: Eastern Europe Market US$ Mn Forecast by End User
Table 26: East Asia Market US$ Mn Forecast by Country
Table 27: East Asia Market US$ Mn Forecast by Service
Table 28: East Asia Market US$ Mn Forecast by Phase
Table 29: East Asia Market US$ Mn Forecast by Therapeutic Area
Table 30: East Asia Market US$ Mn Forecast by End User
Table 31: South Asia & Pacific Market US$ Mn Forecast by Country
Table 32: South Asia & Pacific Market US$ Mn Forecast by Service
Table 33: South Asia & Pacific Market US$ Mn Forecast by Phase
Table 34: South Asia & Pacific Market US$ Mn Forecast by Therapeutic Area
Table 35: South Asia & Pacific Market US$ Mn Forecast by End User
Table 36: MEA Market US$ Mn Forecast by Country
Table 37: MEA Market US$ Mn Forecast by Service
Table 38: MEA Market US$ Mn Forecast by Phase
Table 39: MEA Market US$ Mn Forecast by Therapeutic Area
Table 40: MEA Market US$ Mn Forecast by End User
Figure 1: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 2: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 3: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 4: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 5: Global Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Region
Figure 6: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 7: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 8: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 9: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 10: North America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 11: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 12: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 13: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 14: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 15: Latin America Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 16: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 17: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 18: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 19: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 20: Western Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 21: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 22: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 23: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 24: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 25: Eastern Europe Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 26: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 27: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 28: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 29: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 30: East Asia Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 31: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 32: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 33: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 34: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 35: South Asia & Pacific Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Figure 36: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Service
Figure 37: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Phase
Figure 38: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Therapeutic Area
Figure 39: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by End User
Figure 40: MEA Market Value Share (%), Growth Rate (Y-o-Y), and US$ Mn Projection by Country
Clinical Trial Logistic Market